Gene expression from both parental genomes is required for completion of embryogenesis. Differential methylation of each parental genome has been observed in mouse and human preimplantation embryos. It is possible that these differences in methylation affect the level of gene transcripts from each parental genome in early developing embryos. The aim of this study was to investigate if there is a parent-specific pattern of BRCA1 expression in human embryos and to examine if this affects embryo development when the embryo carries a BRCA1 or BRCA2 pathogenic mutation. Differential parental expression of ACTB, SNRPN, H19 and BRCA1 was semi-quantitatively analysed by minisequencing in 95 human preimplantation embryos obtained from 15 couples undergoing preimplantation genetic diagnosis. BRCA1 was shown to be differentially expressed favouring the paternal transcript in early developing embryos. Methylation-specific PCR showed a variable methylation profile of BRCA1 promoter region at different stages of embryonic development. Embryos carrying paternally inherited BRCA1 or 2 pathogenic variants were shown to develop more slowly compared with the embryos with maternally inherited BRCA1 or 2 pathogenic mutations. This study suggests that differential demethylation of the parental genomes can influence the early development of preimplantation embryos. Expression of maternal and paternal genes is required for the completion of embryogenesis.
INTRODUCTION
Preimplantation embryo development follows a series of critical events, deprogramming of the genomes of sperm and egg and remarkable reprogramming of gene expression occurs to activate the embryonic genome. With the exception of imprinted loci, the expression of both maternal and paternal copies of genes is required for the completion of embryogenesis. 1 In mice, the genome of the oocyte is markedly undermethylated compared with the sperm. 2 Upon fertilization, mammalian zygotes (including humans) undergo genome-wide demethylation to establish the pluripotency of the newly developing embryo. 2 Selective demethylation of the male pronucleus occurs upon fertilization. [3] [4] [5] [6] [7] [8] [9] In contrast to the male pronucleus, demethylation of the female mouse pronucleus starts with the first cleavage divisions. 2, 3, [7] [8] [9] [10] Recent genome-wide DNA methylation studies have reported a wave of demethylation in early preimplantation embryos. Throughout early embryonic development, a differential methylation pattern is maintained in the majority of the differentially methylated regions in imprinted genes, although some show stagespecific changes. 11 Repetitive elements, housekeeping genes and genes controlling pluripotency or differentiation have been reported to have specific methylation patterns during embryo development. 12, 13 We hypothesize that, during the transition of demethylation and deprogramming in preimplantation embryo development, there is differential expression of parental alleles in certain genes that are not imprinted genes. The differential expression of parental alleles arises due to variation in the timing of demethylation and the level of methylation of each parental genome. Changes in the methylation patterns of BRCA1 have been reported in early developing preimplantation embryos. 14 If there is differential demethylation and remethylation of non-imprinted genes of maternal and paternal genomes during early development, then the level of transcription from each parental genome may also be different. Thus, when a pathogenic mutation is present, the differential level of mutant and normal transcripts available for translation in the early embryo will be determined by the parental origin of the variant in the embryo. This, in turn, suggests that the effect of inheritance of a variant may vary in the early embryo, depending on whether it was transmitted from the maternal or paternal genome.
We, therefore, sought to characterize differential parental gene expression in human preimplantation embryos obtained from patients undergoing preimplantation genetic diagnosis (PGD) and to investigate the possible effect of a pathogenic variant on embryo development depending on the parental inheritance of the variant.
MATERIALS AND METHODS

Sample collection and processing
This study was licensed by the Human Fertilization and Embryology Authority (Reference: RO113) and ethical approval was granted by the National Research Ethics Service, Research Ethics Committee (Reference: 10/H0709/26). Wholeblood and surplus embryos were collected from couples who had given informed consent following PGD treatments for a variety of monogenic disorders.
Ovarian reserve tests and gonadotrophin stimulation were performed as described previously. 15 Briefly, immature oocytes were matured in G-IVF Plus medium (Vitrolife, Goẗeborg, Sweden) within 4 h of collection. Intracytoplasmic sperm injection was performed~40 h post hCGH injection. Fertilization was assessed at 16-20 h post insemination and the presence of two pronuclei and polar bodies indicated normally fertilized oocytes. 16 Embryos were cultured in G-1/G-2 PLUS media (Vitrolife). Preimplantation embryos were graded according to Bolton et al. 17 Those embryos diagnosed as affected following PGD or not suitable for transfer were collected on day 6 post fertilization, in order to be used for this project. Each embryo was washed and transferred in phosphate buffered saline with 0.1% polyvinyl alcohol solution (PBS/PVA, Sigma, St Louis, MO, USA) and 0.3 U/μl RNasin plus RNAse inhibitor (Promega, Southampton, UK).
Genotyping couples
DNA extracted from whole blood from the couple was sequenced (BigDye Terminator v3.1 Cycle Sequencing, ABI, Barnsley, UK) for exonic regions of GAPDH, ACTB, UBE3A, SNRPN, IGF2, H19 and BRCA1 to identify informative single-nucleotide polymorphisms (SNPs) between the partners (Supplementary Table 1 ). A couple was defined as fully informative for an SNP when each partner was homozygous for different alleles, whereas a couple was defined as semi-informative when one partner was homozygous and the other was heterozygous with one shared allele at the SNP. The data were submitted to the gene variant database at www.LOVD.nl/CAV3 (Patient IDs-variant IDs: 00074438-0000119134, 00074441-0000119305, 00074442-0000119307, 00074443-0000119309, 00074444-0000119310 and 00074445-0000119312).
DNA and RNA extraction from embryos DNA and RNA from embryos were extracted using the AllPrep DNA/RNA micro kit (Qiagen, Manchester, UK). The quality of RNA was assessed using the RNA 6000 Pico kit (Agilent, Oxford, UK) on a Eukaryote Total RNA Pico Series II chip using the Agilent 2100 Bioanalyzer (Agilent, Colorado Springs, CA, USA).
Analysis of differential gene expression
Reverse transcription of RNA obtained from the embryos was performed using the SuperScript III first-strand synthesis system for RT-PCR (Invitrogen, Paisley, UK). DNA contamination was identified by multiplex PCR (Qiagen) using two markers (Eurogentec, Camberley, UK) D19S112 and APOC2. These markers were selected to detect DNA contamination as they amplify an exonic as well as an intronic region. In addition, these markers were used due to the high heterozygosity.
SNaPshot minisequencing assay sensitivity
Differential expression of parental transcripts using RNA samples was analysed semi-quantitatively on the previously identified informative and semiinformative SNPs by SNaPshot minisequencing assay (Applied Biosystems, Warrington, UK) (Supplementary Table 2 ). Differential expression of one parental transcript relative to the other was defined as an allele peak height ratio 41:2. Monoallelic or preferential allelic expression of a transcript was only considered in embryos where both parental alleles could be identified in the analysed SNP. If an allele shared by each parent was expressed in the embryo, the sample was excluded from the analysis. Statistical analysis was performed by Student's t-test using GraphPad prism v6 software (San Diego, CA, USA). The quantitative difference between each parental allele in the embryos identified by minisequencing was validated by real-time PCR with subsequent highresolution melting analysis (Roche, Welwyn Garden City, UK).
Chromosomal copy number analysis
The chromosome copy number of the genes (chromosomes 7, 11, 15 and 17) was analysed using DNA to ensure that the differential expression detected is not due to an aneuploidy in the embryo. The copy number of chromosomes 7, 11, 15 and 17 was determined by haplotype analysis. Polymorphic markers that are on the same chromosome with the genes analysed, ACTB, SNRPN, H19 and BRCA1, and that were available in our laboratory were used to determine the chromosome copy number. Analysis of the copy number of chromosome 7 was linked to CFTR (D7S2420, D7S2459 and D7S486), chromosome 11 markers were linked to HBB (D11S1338, D11S1997 and D11S4147), chromosome 15 to FBN1 (D15S992, D15S123 and D15S94) and chromosome 17 to BRCA1 (D17S579, D17S1789, D17S1353 and D17S841). The copy number of the chromosomes was scored only if the origin of the parental alleles at that locus could be distinguished. In these cases, if only one parental allele was detected, the embryo was considered to have lost the copy of the chromosome harbouring the missing allele. Embryos were considered to have gained a chromosome when three alleles were detected. An isodisomy of the chromosome could not be detected in the embryo using this method.
A subset of embryos was also analysed by array comparative genomic hybridization (aCGH) using the 24Sure system, following whole-genome amplification (BlueGnome, Cambridge, UK). The slides were scanned using ScanArray Express (Perkin Elmer, Danbury, CT, USA) and the arrays were analysed using Bluefuse Multi analysis software v.2.6 (BlueGnome). The cutoff of the log2 ratio fluorescent test signal over the control DNA was set as +0.3 for the gain and − 0.3 for the loss of a chromosome by the software.
Methylation studies
The methylation status of ACTB, H19 and BRCA1 was analysed in a subset of embryos. The EpiTect Bisulfite conversion kit (Qiagen) was used for DNA treatment. A set of outer primers with no CpG dinucleotides was designed for ACTB, H19 and BRCA1 (Supplementary Table 3 ). Two sets of inner primers resulting in PCR products of different sizes directed to the methylated and unmethylated sequences were used for the promoter regions of ACTB, H19 and BRCA1. 18 Statistical analyses: embryos with BRCA1 or 2 pathogenic mutations and preimplantation embryo development
The developmental stage of all the embryos with BRCA1 or 2 pathogenic mutations was examined on day 5/6 post fertilization and related to the parental inheritance of the variant. Statistical analysis was performed to investigate the difference between the developmental stage of embryos with paternally inherited BRCA1 or 2 pathogenic mutations and the maternally inherited BRCA1 or 2 pathogenic mutations by χ 2 -test using GraphPad prism v6 software.
RESULTS
Genotyping analysis
Parental genotyping by sequencing of seven genes identified informative SNPs between 15 partners that enabled detection of heterozygous embryos in four genes (Table 1) .
Haplotyping analysis was performed to determine the copy number of chromosomes 7, 11, 15 and 17 in embryos. The detailed results are listed in Table 2 . Of these embryos, 26 were also analysed by aCGH. Twelve embryos were shown to be euploid and the rest of the embryos showed various aneuploidies. Only two of these embryos (embryo 69 and 72) showed aneuploidies for the chromosomes of interest (gain of chromosome 17) and these embryos were excluded from the analysis ( Table 2) .
Minisequencing assay sensitivity for allelic imbalance
The sensitivity of the minisequencing analysis was validated by realtime PCR. Amplification of cDNA from the embryos showed that the mean Cq values for the start of the exponential phase of amplification were 36 for ACTB, 34 for SNRPN, 41 for H19 and 35 for BRCA1. Therefore, PCR prior to minisequencing analysis was stopped before the exponential phase was reached. High-resolution melting analysis of all the PCR products from embryos confirmed the allelic imbalances identified by minisequencing.
Differential gene expression in preimplantation embryos
A total of 95 embryos were analysed to establish the parental expression profiles of ACTB, SNRPN, H19 and BRCA1. A summary of the results is shown in Table 1 and Figure 1 . The expression level of maternal and paternal transcripts of ACTB was similar for all 11 embryos analysed for this gene.
Minisequencing analysis of imprinted gene transcripts showed that paternal transcript of SNRPN predominated in more than half of the embryos regardless of their developmental stage (*P = 0.01; 56.5%, 13/23, Figures 1 and 2 ). Monoallelic expression of paternal SNRPN transcript was observed in 69% (9/13) of these embryos. As the embryos reached later stages of development, differential expression favouring the paternal SNRPN transcript increased from 61% (8/13) at cleavage and morula stages to 70% (7/10) for the blastocyst stage embryos.
Unlike SNRPN, H19 was not readily detected in human preimplantation embryos (31%, 15/48). One embryo was excluded from the analysis as it was shown to have only the maternal copy of chromosome 11 by haplotyping. This accounted for the detection of only the maternal H19 transcript by the SNapShot assay. Overall, 60% (9/14) of the embryos expressed predominantly the maternal H19 transcript with 78% (7/9) being strictly monoallelic for the maternal transcript. Preferential expression of the maternal H19 transcript was observed to be 50% (2/4) at cleavage, 66% (4/6) in morula and 75% (3/4) in blastocyst stage embryos.
Two SNPs, located in exon 11 and exon 12, were analysed to investigate differential expression of parental BRCA1 transcripts. About 13% (10/75) of the embryos analysed were excluded from the analysis as the differential expression was not concordant at these two SNPs. Two embryos were excluded from the analysis as they showed a gain of chromosome 17, reflecting the preferential BRCA1 expression by the SNaPshot assay. Differential BRCA1 expression in the embryos was 66% (10/15) at cleavage, 55% (10/18) at morula and 50% (7/14) at the blastocyst stage. Overall, there were significantly more embryos with elevated expression of paternal BRCA1 transcripts compared with embryos with increased expression of maternal transcripts, regardless of the developmental stage (*P = 0.03, Figures 1 and 2 ).
Differential methylation analysis
Methylation analysis was performed by bisulfite conversion, followed by methylation-specific PCR. Due to insufficient starting material, the amount of DNA obtained from a single embryo and the bisulfite treatment being deleterious for DNA, sequencing analysis on the converted DNA could not be performed. The promoter regions of three genes, ACTB, H19 and BRCA1, were amplified by nested PCR. When monoallelic expression of one parental transcript was observed Number of embryos included in the haplotyping analysis with the percentage of informative haplotypes and heterozygote embryos are summarized. The percentage of inconclusive analysis due to amplification failure was also shown. Figure 1 Overall differential expression of paternal and maternal transcripts for four genes in human embryos. It was shown that there was no significance in the differential expression of parental transcripts for ACTB (P = 0.2). Paternal SNRPN transcripts were expressed at significantly higher levels relative to the maternal transcripts (*P = 0.01) in embryos. Although higher levels of maternal H19 transcripts were detected in embryos, this was not significant (P = 0.4). The differential expression of paternal BRCA1 expression was shown to be significant relative to the maternal transcripts (*P = 0.03) in the embryos. (29) 19 (9) 22 (11) a Only the paternal expression of SNRPN was observed in 9/13 embryos and only the maternal expression of H19 was observed in 7/9 embryos.The genes analysed for differential expression, percentage of informative haplotypes where each parental allele was distinguished and the percentage of embryos with differential gene expression favouring the paternal and maternal transcripts are listed. BRCA1 was analysed at two loci and the results shown here were collective from both loci. In 10 embryos, differential expression of BRCA1 at two loci did not agree and these were not included in the analysis.
Differential parental BRCA1 expression in human embryos P Tulay et al by SNaPshot analysis, a hemi-methylated profile was expected to be observed as only one parental transcript is present. When both parental transcripts were expressed at similar levels by SNaPshot analysis, an unmethylated profile was expected to be observed, representing both parental transcripts at similar levels. As allelespecific methylation was not studied, it is not possible to draw a definite conclusion as to whether the methylation status was the reason for differential gene expression. Methylation analysis of ACTB in five embryos showed that these embryos were unmethylated, which supports the expression profile observed by SNaPshot analysis (Figure 3 ). Methylation analysis of 3/8 embryos confirmed the differential H19 expression. Of these embryos, two were hemi-methylated. These embryos also showed monoallelic expression of H19 transcript. One embryo was unmethylated, and this supported the biallelic expression of H19 transcripts by the minisequencing assay. In 5/8 embryos, differential expression of the parental transcripts did not relate to the methylation status. The hemi-methylated profile of BRCA1 confirmed differential expression of parental transcripts in 58% (18/31) of the embryos.
Development of embryos with BRCA1 and BRCA2 variants Following PGD for BRCA1 and BRCA2 in six couples, 31 embryos were identified with a BRCA1 or BRCA2 pathogenic mutations. Half of the embryos with paternally transmitted BRCA1 germline pathogenic mutations (8/16 ) were arrested at the cleavage stage. Only 12.5% (2/16) of these embryos reached the blastocyst stage 5 days post fertilization. Embryos with maternally inherited BRCA1 variants developed at a significantly faster rate (8/15, 53% at blastocyst stage, P = 0.01) compared with the embryos with paternally inherited BRCA1 and BRCA2 pathogenic mutations (Figure 4) .
DISCUSSION
Differential expression
This study showed that similar levels of parental ACTB transcripts were expressed in human embryos. The paternally imprinted gene H19 was not always detected in embryos. Some studies have reported the detection of both parental alleles in slow-growing embryos or Differential parental BRCA1 expression in human embryos P Tulay et al morphologically poor embryos, 19 whereas some did not detect H19 at all. 20 In this study, H19 was detected in 31% (15/48) of the embryos. Although biallelic expression of the H19 transcript (7/14) was detected in half of the embryos confirming previously published reports, 21 preferential expression of maternal H19 transcripts was observed in the majority of the embryos. Although it is well accepted that H19 is a paternally imprinted gene, expression of both parental H19 alleles has been reported in the human oocytes and preimplantation embryos. Studies have suggested that developmentally delayed embryos show an unexpected expression and methylation profile. 19 In this study, embryos with similar parental expression of H19 developed at a slower rate where seven embryos were between 5 and 10 cell stage and two were at morula stage on day 5/6 post fertilization. In addition, all of the embryos that reached blastocyst stage showed opposing patterns of parental expression for these two imprinted genes. This observation supports the finding of Khoueiry et al 21 who reported that slow-developing embryos had a balanced pattern of methylated and unmethylated strands of H19DMR. The imprinting of SNRPN was not completed in the early developing preimplantation embryos, such that the maternal SNRPN transcript was detected in 60% (9/15) of the embryos, as reported previously. 20, 22 The unexpected expression of maternal SNRPN alleles could be due to the on-going maternal mRNA degradation in these embryos, whereas the paternal H19 transcripts could be caused by partial resetting of H19 in the sperm. 19 The onset of the monoallelic expression of these genes might be at a later stage in human embryos or the time of the monoallelic expression could be variable among embryos. It has been reported that the time of the monoallelic expression of the imprinted genes, such as IGF2, SNPRN and MEST, varies in mouse embryos. 22, 23 Developmentally delayed embryos were shown to have unusual expression and methylation profiles. 19, 21 This was also observed in our study, where 20% (3/15) of slow-developing embryos had similar expression levels of H19 and 39% (9/23) of slowdeveloping embryos had similar parental levels of SNRPN transcripts. None of these embryos reached the blastocyst stage. It is also possible that assisted reproductive technology techniques lower the level of methylation for the imprinted genes, 19, [24] [25] [26] causing the unexpected expression of transcripts. 27 In this study, differential expression of paternal BRCA1 transcript was observed in embryos. This preferential expression was more prevalent in the cleavage-stage embryos. As the embryos developed to the blastocyst stage, differential expression of BRCA1 was reduced. In 13% of the embryos, differential BRCA1 expression could not be determined as the expression profiles for the two SNPs analysed were not concordant. BRCA1 is known to undergo alternative splicing in a number of its exons, forming isoforms that skip exon 5, exons 2-10, exons 9-11, exon 11 only, exons 14-17 and exons 14-18. 28,29 Alternative splicing of exon 11 yields a full-length isoform and also shorter isoforms either through the use of an alternative intra-exonic splice donor site [29] [30] [31] or through complete skipping of exon 11. Therefore, if one of these isoforms was present in the embryos analysed in this study, differences in the expression profiles of BRCA1 in exon 11 and exon 12 may have arisen.
The methylation analysis showed that preferential expression observed in H19 and BRCA1 may be due to the methylation status of the parental transcripts. A gradual demethylation was previously observed for BRCA1 during cleavage divisions of human embryos where~30% of the methylated BRCA1 residues remained up to the blastocyst stage. 14 A recently published study also showed that monoallelic as well as biallelic expression was detected in human primary fibroblasts. 32 They reported that each cell mostly expressed one allele. The abundance of the cellular transcripts and the monoallelic expression could account for phenotypic variability in humans including penetrance and expressivity of a dominant developmental disorder, or cellular heterogeneity in cancers and predisposition to a complex phenotype. 32 Development of embryos with BRCA1 and BRCA2 pathogenic mutations The development of the embryos with BRCA1 or 2 pathogenic mutations were investigated in six couples undergoing PGD. Three males and three females with BRCA1 or 2 pathogenic mutations opted for PGD. Two of the male partners had BRCA1 pathogenic mutations and one had BRCA2 pathogenic mutations. The female partner of the rest of the couples undergoing PGD had BRCA1 pathogenic mutations. The majority of the embryos with paternally inherited BRCA1 or 2 pathogenic mutations (eight embryos with BRCA1 and eight embryos with BRCA2 pathogenic mutations, respectively) were shown to arrest at the cleavage between 4 and 10 cell stages (50%). Only 38% of the embryos developed to the morula stage and only 12.5% of the embryos reached the blastocyst stage. Embryos with paternally BRCA1-and BRCA2-inherited pathogenic mutations (16 embryos) were shown to develop significantly slower compared with embryos with maternally inherited variants (15 embryos, *P = 0.01). As the paternal genome undergoes a rapid demethylation starting at the early stages of preimplantation embryos, embryos with paternally inherited BRCA1 and BRCA2 pathogenic mutations and defective homologous recombination pathways may be prevented from developing to the later stages of preimplantation development. However, embryos with maternally inherited BRCA1 pathogenic mutations may compensate for the variant and initiate homologous recombination repair through paternal transcripts that were free from the variant. Therefore, when the embryos are carrying a paternally inherited BRCA1 or BRCA2 pathogenic mutations, it may be more prone to embryonic lethality during cleavage divisions. Thus, we speculate that less viable embryos with paternally inherited BRCA1 or 2 pathogenic mutations are produced compared with the maternally inherited BRCA1 or 2 pathogenic mutations. Therefore, we assume that there are more adults with maternally inherited BRCA1 or 2 pathogenic mutations. The higher number of maternally inherited BRCA1 or 2 variants was also reported previously. 33, 34 Although these articles were evaluating the risk of cancer and the onset of cancer depending on the parental Figure 4 Developmental rate of embryos carrying paternally inherited BRCA1 or 2 pathogenic mutations compared with maternally inherited BRCA1 or 2 pathogenic mutations. Significantly fewer embryos developed to the later stages of preimplantation development (morula and blastocyst stages) compared with the embryos carrying maternally inherited mutations (*P = 0.01).
Differential parental BRCA1 expression in human embryos P Tulay et al origin of the BRCA1 or 2 variants, their data showed that there were more patients with maternally inherited BRCA1 or 2 variants. 33, 34 Once the genome-wide demethylation of genes is completed during cleavage divisions, we assume that embryos with maternally and paternally inherited BRCA1 or 2 variants have similar chances of implantation and pregnancy.
CONCLUSION AND FUTURE PERSPECTIVES
The main limitation of this study was the small number of embryos analysed due to the scarcity of the human embryos. However, even with this small number of embryos, these data show significant outcome relating gene expression with development of preimplantation embryos. This study showed that SNRPN, H19 and BRCA1 transcripts were differentially expressed in human embryos. The presence of a BRCA1 or 2 pathogenic mutations inherited from the paternal genome had a greater detrimental effect on the development of the embryo to blastocyst compared with pathogenic mutations inherited from the maternal genome. This may stem from differences in methylation patterns of the parental genomes in embryos. Therefore, the contribution of the paternal genome in the preimplantation embryo development may be vital, especially in the early stages. Further extrapolation of this data suggest that the risk of transmitting a BRCA1 or 2 pathogenic variants may be altered by the parental origin of the variant. Paternally transmitted BRCA1 or 2 pathogenic mutations are more likely to result in embryos that fail to reach blastocyst, thereby limiting the implantation potential of these embryos. Consequently this may lower the overall risk of males with BRCA1 or 2 mutations having children who have inherited their pathogenic mutation.
